Formycon narrows FY25 EBITDA loss, trims working capital outlook By Investing.com

Formycon raised its expected FY2025 EBITDA profile, narrowing the reported EBITDA loss to 4 million euros from 12 million euros and the adjusted EBITDA loss to 2 million euros from 7 million euros, while trimming working capital needs to about 70 million euros from 73 million euros. Revenue remains guided at 45 million euros, but that is still well below the prior 55 million to 65 million euro range after a slower-than-expected ramp of FYB202 and longer commercialization negotiations. The company will publish audited FY2025 results and its 2026 outlook on Tuesday after a delay tied to its internal planning-system transition.

Analysis

The revision is less a clean operational upgrade than a quality-of-earnings reset: management is narrowing the gap between reported and adjusted profitability while leaving the top-line miss and working-capital drag largely unresolved. That usually signals a business where cash conversion is stabilizing faster than true demand recovery, which matters because biosimilar commercialization is a milestone-driven market, not a linear ramp. The key takeaway is that FY26 commentary will likely matter more than the FY25 cleanup; if the new planning system produces a credible forecast reset, the stock can de-risk, but if guidance remains abstract, the market will keep applying a credibility discount.

Competitive dynamics likely improve for larger biosimilar platforms with broader BD reach and manufacturing optionality. Slower-than-expected partner negotiations can be read as evidence that originator-adjacent biosimilar assets are under pressure to concede more economics, which benefits buyers of future launch rights and hurts smaller developers reliant on one or two lead assets to fund the pipeline. The working-capital reduction is also important: it suggests some inventory or receivables normalization, but not enough to offset the strategic issue that delayed commercialization reduces the probability of an efficient launch window.

The stock’s near-term catalyst path is binary over the next 1-2 weeks around audited results and FY26 outlook. If management guides toward a clearer launch cadence and reduced cash burn, the market can rerate the name on lower execution risk; if not, investors will likely focus on the revenue miss and implied slippage in partner conversion, which could compress multiples further. The contrarian view is that consensus may be over-penalizing the lower EBITDA loss while underestimating the signaling value of a cleaner balance-sheet trajectory — for a small-cap biotech platform, liquidity visibility often matters more than one year’s P&L.

For risk/reward, this is better expressed as a tactical event trade than a structural long until the outlook is published. The most attractive setup is a short-dated volatility expression: downside if FY26 guidance disappoints, but upside if the company restores credibility with a tighter cash-use framework. The main reversal risk is a surprise partner announcement or accelerated FYB202 traction, which could force a sharp squeeze given the name’s likely low liquidity.

Key Decisions for Investors

• Avoid chasing the stock into the annual-report print; wait for FY26 guidance and only initiate a long if management provides a credible path to improved cash conversion and partner monetization over the next 2-4 quarters.
• If options are liquid, buy a short-dated straddle or strangle into the results event to capture guidance-driven volatility; the setup favors a large move because the market is deciding between 'stabilizing turnaround' and 'persistent execution lag.'
• For equity accounts willing to own a post-event clean-up story, consider a small starter long only on a >10% drawdown after results if working capital and cash burn improve more than the revenue miss worsens.
• If a borrowable comparator exists in the European biosimilar space, pair long higher-quality, diversified biosimilar platform names against this name as a relative-value expression of execution risk over the next 3-6 months.
• Treat any post-print rally as sellable unless FY26 commentary explicitly upgrades commercialization timing; absent that, the recovery is likely to be valuation-driven and fragile rather than fundamental.